Perspectives

New therapies for diabetes: has the regulatory program gone too far?

Perspectives

New therapies for diabetes: has the regulatory program gone too far?

Michael d’Emden

Figures

Abstract

New therapies with additional benefits beyond glucose lowering are being developed to improve the management of diabetes. This article describes the changes to the regulatory framework that have demanded large cardiovascular safety studies for novel diabetes drugs and discusses new agents that may have a role in the management of patients with diabetes now and in the future.

Key Points

  • Cardiovascular diseases (CVDs) are the most common complications in people with type 2 diabetes.
  • Poor glycaemic control is associated with higher rates of CVD.
  • Current therapies that improve glycaemic control do not decrease the rate of CVD events.
  • Improved glycaemic control with CVD benefit is the goal of new diabetes therapies.

    Picture credit: © Phototake RM/Steve Oh, M.S./Diomedia.com